coversyl plus
servier laboratories (australia) pty ltd - indapamide hemihydrate; perindopril arginine -
diamicron 60mg mr
servier laboratories (australia) pty ltd - gliclazide -
muphoran
servier laboratories (australia) pty ltd - fotemustine -
natrilix
servier laboratories (australia) pty ltd - indapamide hemihydrate -
natrilix sr
servier laboratories (australia) pty ltd - indapamide hemihydrate -
protos
servier laboratories (australia) pty ltd - strontium ranelate -
reaptan
servier laboratories (australia) pty ltd - perindopril arginine; amlodipine besylate -
valdoxan
servier laboratories (australia) pty ltd - agomelatine -
prexum combi ld 2.5/0.625 perindopril arginine 2.5mg / indapamide hemihydrate 0.625mg film-coated tablet bottle
servier laboratories (aust) pty ltd - indapamide hemihydrate, quantity: 0.625 mg; perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; maltodextrin; magnesium stearate; colloidal anhydrous silica; macrogol 6000; lactose monohydrate; colour - treatment of hypertension.
lonsurf 15/6.14 trifluridine 15 mg/ tipiracil hydrochloride 7.065 mg (equivalent to tipiracil 6.14 mg) film-coated tablet blister pack
servier laboratories (aust) pty ltd - tipiracil hydrochloride, quantity: 7.065 mg; trifluridine, quantity: 15 mg - tablet, film coated - excipient ingredients: carnauba wax; pregelatinised maize starch; lactose monohydrate; iron oxide yellow; titanium dioxide; macrogol 8000; indigo carmine aluminium lake; hypromellose; stearic acid; iron oxide red; shellac; purified talc; magnesium stearate - colorectal cancer lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) who have been previously treated with, or are not considered candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.,gastric cancer lonsurf is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy.